Effects of zafirlukast on bronchial asthma and allergic rhinitis

G. Piatti, L. Ceriotti, G. Cavallaro, U. Ambrosetti, M. Mantovani, A. Pistone, S. Centanni

Research output: Contribution to journalArticle

Abstract

Asthma and allergic rhinitis are common conditions, occurring with increasing prevalence and frequently coexist. In both conditions histamine and cysteinil leukotrienes are important pathogenic inflammatory mediators. We evaluated the effects of the leukotriene receptor antagonist zafirlukast, 20mg administered twice daily for 2 weeks, in patients with allergic rhinitis and bronchial asthma during the grass pollen season. Patients underwent skin prick testing, spirometry, rhinomanometry, mucus transport test with saccharine, nasal epithelial brushing to study ciliary beat and, finally, nasal lavage. Thirty-five subjects completed the study. At the end of the study period, zafirlukast significantly reduced asthma and rhinitis symptoms (P≤0.05); FEV 1 values were unchanged (P=0.10), whereas nasal resistances showed a decrease following treatment (P=0.01). Ciliary beat frequency (CBF) also improved (P=0.00), although mucociliary transport showed no improvement (P=0.87). The number of eosinophils in nasal lavage fluid decreased (P=0.00) while that of neutrophils was unchanged (P=0.09). These positive effects suggest that zafirlukast may be usefully employed in the treatment of both bronchial asthma, as previously demonstrated, and allergic rhinitis.

Original languageEnglish
Pages (from-to)541-547
Number of pages7
JournalPharmacological Research
Volume47
Issue number6
DOIs
Publication statusPublished - Jun 1 2003

Fingerprint

Asthma
Nose
Nasal Lavage Fluid
Nasal Lavage
Rhinomanometry
Leukotriene Antagonists
Mucociliary Clearance
Leukotrienes
Spirometry
Mucus
Rhinitis
Pollen
Poaceae
Eosinophils
Histamine
Neutrophils
Skin
zafirlukast
Allergic Rhinitis
Therapeutics

Keywords

  • Allergic rhinitis
  • Bronchial asthma
  • Leukotriene receptor antagonists
  • Mucociliary clearance
  • Nasal cytology
  • Zafirlukast

ASJC Scopus subject areas

  • Pharmacology

Cite this

Piatti, G., Ceriotti, L., Cavallaro, G., Ambrosetti, U., Mantovani, M., Pistone, A., & Centanni, S. (2003). Effects of zafirlukast on bronchial asthma and allergic rhinitis. Pharmacological Research, 47(6), 541-547. https://doi.org/10.1016/S1043-6618(03)00017-3

Effects of zafirlukast on bronchial asthma and allergic rhinitis. / Piatti, G.; Ceriotti, L.; Cavallaro, G.; Ambrosetti, U.; Mantovani, M.; Pistone, A.; Centanni, S.

In: Pharmacological Research, Vol. 47, No. 6, 01.06.2003, p. 541-547.

Research output: Contribution to journalArticle

Piatti, G, Ceriotti, L, Cavallaro, G, Ambrosetti, U, Mantovani, M, Pistone, A & Centanni, S 2003, 'Effects of zafirlukast on bronchial asthma and allergic rhinitis', Pharmacological Research, vol. 47, no. 6, pp. 541-547. https://doi.org/10.1016/S1043-6618(03)00017-3
Piatti, G. ; Ceriotti, L. ; Cavallaro, G. ; Ambrosetti, U. ; Mantovani, M. ; Pistone, A. ; Centanni, S. / Effects of zafirlukast on bronchial asthma and allergic rhinitis. In: Pharmacological Research. 2003 ; Vol. 47, No. 6. pp. 541-547.
@article{c9676b0a5bcf4a619a48f2daa6d05fff,
title = "Effects of zafirlukast on bronchial asthma and allergic rhinitis",
abstract = "Asthma and allergic rhinitis are common conditions, occurring with increasing prevalence and frequently coexist. In both conditions histamine and cysteinil leukotrienes are important pathogenic inflammatory mediators. We evaluated the effects of the leukotriene receptor antagonist zafirlukast, 20mg administered twice daily for 2 weeks, in patients with allergic rhinitis and bronchial asthma during the grass pollen season. Patients underwent skin prick testing, spirometry, rhinomanometry, mucus transport test with saccharine, nasal epithelial brushing to study ciliary beat and, finally, nasal lavage. Thirty-five subjects completed the study. At the end of the study period, zafirlukast significantly reduced asthma and rhinitis symptoms (P≤0.05); FEV 1 values were unchanged (P=0.10), whereas nasal resistances showed a decrease following treatment (P=0.01). Ciliary beat frequency (CBF) also improved (P=0.00), although mucociliary transport showed no improvement (P=0.87). The number of eosinophils in nasal lavage fluid decreased (P=0.00) while that of neutrophils was unchanged (P=0.09). These positive effects suggest that zafirlukast may be usefully employed in the treatment of both bronchial asthma, as previously demonstrated, and allergic rhinitis.",
keywords = "Allergic rhinitis, Bronchial asthma, Leukotriene receptor antagonists, Mucociliary clearance, Nasal cytology, Zafirlukast",
author = "G. Piatti and L. Ceriotti and G. Cavallaro and U. Ambrosetti and M. Mantovani and A. Pistone and S. Centanni",
year = "2003",
month = "6",
day = "1",
doi = "10.1016/S1043-6618(03)00017-3",
language = "English",
volume = "47",
pages = "541--547",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press",
number = "6",

}

TY - JOUR

T1 - Effects of zafirlukast on bronchial asthma and allergic rhinitis

AU - Piatti, G.

AU - Ceriotti, L.

AU - Cavallaro, G.

AU - Ambrosetti, U.

AU - Mantovani, M.

AU - Pistone, A.

AU - Centanni, S.

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Asthma and allergic rhinitis are common conditions, occurring with increasing prevalence and frequently coexist. In both conditions histamine and cysteinil leukotrienes are important pathogenic inflammatory mediators. We evaluated the effects of the leukotriene receptor antagonist zafirlukast, 20mg administered twice daily for 2 weeks, in patients with allergic rhinitis and bronchial asthma during the grass pollen season. Patients underwent skin prick testing, spirometry, rhinomanometry, mucus transport test with saccharine, nasal epithelial brushing to study ciliary beat and, finally, nasal lavage. Thirty-five subjects completed the study. At the end of the study period, zafirlukast significantly reduced asthma and rhinitis symptoms (P≤0.05); FEV 1 values were unchanged (P=0.10), whereas nasal resistances showed a decrease following treatment (P=0.01). Ciliary beat frequency (CBF) also improved (P=0.00), although mucociliary transport showed no improvement (P=0.87). The number of eosinophils in nasal lavage fluid decreased (P=0.00) while that of neutrophils was unchanged (P=0.09). These positive effects suggest that zafirlukast may be usefully employed in the treatment of both bronchial asthma, as previously demonstrated, and allergic rhinitis.

AB - Asthma and allergic rhinitis are common conditions, occurring with increasing prevalence and frequently coexist. In both conditions histamine and cysteinil leukotrienes are important pathogenic inflammatory mediators. We evaluated the effects of the leukotriene receptor antagonist zafirlukast, 20mg administered twice daily for 2 weeks, in patients with allergic rhinitis and bronchial asthma during the grass pollen season. Patients underwent skin prick testing, spirometry, rhinomanometry, mucus transport test with saccharine, nasal epithelial brushing to study ciliary beat and, finally, nasal lavage. Thirty-five subjects completed the study. At the end of the study period, zafirlukast significantly reduced asthma and rhinitis symptoms (P≤0.05); FEV 1 values were unchanged (P=0.10), whereas nasal resistances showed a decrease following treatment (P=0.01). Ciliary beat frequency (CBF) also improved (P=0.00), although mucociliary transport showed no improvement (P=0.87). The number of eosinophils in nasal lavage fluid decreased (P=0.00) while that of neutrophils was unchanged (P=0.09). These positive effects suggest that zafirlukast may be usefully employed in the treatment of both bronchial asthma, as previously demonstrated, and allergic rhinitis.

KW - Allergic rhinitis

KW - Bronchial asthma

KW - Leukotriene receptor antagonists

KW - Mucociliary clearance

KW - Nasal cytology

KW - Zafirlukast

UR - http://www.scopus.com/inward/record.url?scp=0038639212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038639212&partnerID=8YFLogxK

U2 - 10.1016/S1043-6618(03)00017-3

DO - 10.1016/S1043-6618(03)00017-3

M3 - Article

C2 - 12742009

AN - SCOPUS:0038639212

VL - 47

SP - 541

EP - 547

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 6

ER -